Replenish

What Replenish does

Replenish, Inc. is a privately held, pre-revenue medical device company founded in August 2007 and headquartered in Pasadena, California. The company is developing the Ophthalmic MicroPump System, a refillable, programmable implantable ocular drug pump built on MEMS technology licensed from the University of Southern California's Keck School of Medicine and the California Institute of Technology (Caltech). The platform comprises two clinical variants — the Anterior MicroPump (AMP) for glaucoma and the Posterior MicroPump (PMP) for retinal diseases such as age-related macular degeneration (AMD) and diabetic macular edema (DME) — supported by the EyeLink wireless programmer/charger and a proprietary Drug Refill System using disposable 31-gauge needle tubing kits.

The underlying technology enables programmable, nanoliter-sized drug delivery with closed-loop feedback from a fluidic flow sensor, a one-way check valve to prevent backflow, bi-directional wireless telemetry, and a microcontroller-driven dosing schedule. The implant is designed to hold up to 12 months of medication per refill and to last more than five years before replacement, addressing two documented clinical pain points: poor patient adherence with daily glaucoma eye drops and the burden of frequent intravitreal injections for retinal disease.

Replenish operates a pre-commercial business model, with future revenue expected to come from hardware sales of the MicroPump to ophthalmologists and eye care institutions, recurring consumables revenue from drug refills and disposable tubing kits, and licensing-related income. The company has no commercial customers today; its flagship product remains for investigational use only and is not yet approved by the FDA. It is funded by more than $20 million in cumulative venture and corporate investment since 2009, including a $10 million round led by a large pharmaceutical company, and is building its IP estate on the back of 40+ patents licensed from USC and Caltech and 15+ additional company-filed patents.

Name

Replenish

Legal name

Replenish Inc.

Website

https://replenishinc.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Replenish, Inc. is a pre-revenue medical device company developing the MicroPump, a refillable, programmable implantable ocular drug pump for glaucoma and retinal disease patients, using MEMS technology licensed from USC and Caltech and targeting ophthalmologists as prescribers and implanters.

Ownership category

akta.pro rank

Product category

Implantable Ophthalmic Drug Delivery Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

akta.pro secondary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Implantable drug delivery
• Ophthalmic medical devices
• Ocular drug pumps
• MEMS biomedical devices
• Glaucoma treatment devices

Headquarters

HQ city

Pasadena

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Medical Device Sales: Revenue from sale of implantable ocular drug pumps (MicroPump System) to healthcare providers and eye care institutions. The device is designed for surgical implantation, indicating enterprise-level sales transactions.
2. Drug Refill/Consumables: Ongoing revenue from proprietary drug refill system and disposable 31-gauge needle tubing kits used during every drug refill procedure. The pump can hold up to 12 months of medication before requiring refill.
3. Investment/Partnership Funding: Pre-revenue company financed through venture investment ($20M+ raised since 2009, including $10M from a large pharmaceutical company) while pursuing FDA clinical trials.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Replenish, Inc. develops the MicroPump System, a small, refillable, implantable ocular drug pump that can be programmed to dispense precise nanoliter-sized doses of medication with closed-loop feedback control. The platform includes the Anterior MicroPump (AMP) for glaucoma patients and the Posterior MicroPump (PMP) for retina patients, along with the EyeLink wireless programmer/charger and the Drug Refill System console. The device is designed to hold up to 12 months of medication before refill and last more than 5 years before replacement.

Product overview

Replenish, Inc. offers the Ophthalmic MicroPump System, a single-platform implantable ocular drug delivery solution comprising the Anterior MicroPump (AMP) for glaucoma patients and the Posterior MicroPump (PMP) for retina patients. The system includes the EyeLink wireless programmer/charger for bi-directional telemetry and the Drug Refill System console for filling and refilling implants using a disposable 31-gauge needle tubing kit. The platform is designed to last over five years before replacement and can hold up to 12 months of medication before requiring refills.

Differentiator

Problem solved

Functional benefit

Brands

• Anterior MicroPump™ (AMP): MicroPump system for glaucoma patients with similar cannula system and insertion point to glaucoma drainage devices
• Posterior MicroPump™ (PMP)
• EyeLink™
• Drug Refill System™

Products and services

• Ophthalmic MicroPump System A refillable, implantable ocular drug pump system designed to be implanted under the skin of the eye, featuring programmable nanoliter-sized dose delivery with closed-feedback control via a fluidic flow sensor. Holds up to 12 months of medication before refill and lasts over 5 years before replacement. For investigational use only, pending FDA approval.
• Anterior MicroPump (AMP) Component of the Ophthalmic MicroPump System designed for glaucoma patients, featuring a cannula system and insertion point similar to glaucoma drainage devices. Delivers programmable automated medication directly to the eye, eliminating the need for daily eye drops.
• Posterior MicroPump (PMP) Component of the Ophthalmic MicroPump System designed for retina patients, similar to the AMP but with a PARS PLANA CLIP on the drug delivery outlet and larger reservoir volume for continuous drug delivery to the retina.
• EyeLink Wireless Programmer and Charger Wireless programmer and charger enabling bi-directional communication with MicroPump implants for wireless programming of dosing schedules and battery recharging of the implant.
• Drug Refill System Separate console unit used to fill and refill MicroPump implants with drug, utilizing a disposable refill tubing kit with a 31-gauge needle. Required for ongoing medication refills approximately every 6 to 12 months.

Quantifiable outcome

• $290 billion annual cost of patient non-compliance with drug therapy (New England Healthcare Institute, Aug 2009)
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Three partnerships are on record, tiered core.

• California Institute of Technology (Caltech)coreTechnology or IntegrationTechnology licensed from Caltech's Viterbi School of Engineering. Co-Founder Yu-Chong Tai is Chairman of Electrical Engineering and Professor at Caltech, contributing core MEMS and BioMEMS technology expertise. Caltech has acquired small equity ownership for their licenses.
• University of Southern California (USC) - Keck School of MedicinecoreTechnology or IntegrationCore technology developed at USC Keck School of Medicine. The company was founded in 2007 from technology born jointly from USC and Caltech. Dr. Mark Humayun serves as Director of NSF-sponsored BMES ERC at USC. Dr. Sean Caffey earned MD from USC Keck School of Medicine and previously worked at USC/Caltech Engineering Research Center.
• National Science Foundation (NSF) - Biomimetic MicroElectronic Systems (BMES) Engineering Research CentercoreTechnology or IntegrationThe idea for the Ophthalmic MicroPump originated from the NSF-sponsored BMES USC/CalTech Engineering Research Center that specializes in implanting microelectronics in the body. Dr. Mark Humayun serves as Director of this ERC.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Alcon: Alcon is the global ophthalmic leader with broad coverage across surgical devices, pharmaceuticals, and vision care. As a large incumbent, it competes broadly across Replenish's target segments (glaucoma drops, surgical implants, retinal pharmacotherapy) and represents a likely strategic acquirer or partner.
• Bausch + Lomb (Bausch Health): Bausch + Lomb is a major ophthalmic pharmaceutical and device company with significant presence in glaucoma, retinal disease, and ocular surgery. As a broad incumbent, it overlaps with Replenish across drug delivery, surgical implants, and physician channels, and could be a strategic partner.

Direct peers

• EyePoint Pharmaceuticals: EyePoint Pharmaceuticals develops sustained-release ocular drug delivery technologies including DURYSTA (bimatoprost implant) and is advancing pipeline products for retinal diseases. Closely comparable as a small-cap ophthalmic drug delivery company targeting the same physician and patient segments as Replenish.
• Glaukos Corporation: Glaukos pioneered MIGS devices (iStent) that are surgically implanted for glaucoma, sharing Replenish's ophthalmic surgical-implant model and physician channel. Glaukos is also developing drug-eluting and sustained-release ophthalmic therapies, placing it in direct commercial adjacency.
• Allergan (AbbVie) - Durysta: Allergan's Durysta is an FDA-approved intracameral biodegradable bimatoprost implant for glaucoma. It competes directly with Replenish's Anterior MicroPump (AMP) by offering a sustained-release alternative to daily drops, though with a non-refillable, single-dose delivery model.
• Aerie Pharmaceuticals (Alcon): Aerie (acquired by Alcon) developed Rocklatan and Rhopressa, novel topical glaucoma drugs, and is pursuing sustained-release ophthalmic delivery. Competes with Replenish's AMP in the same glaucoma patient population, though via topical rather than implantable delivery.
• Genentech (Roche) - Susvimo: Genentech's Susvimo is an FDA-approved refillable ocular port delivery system implant for ranibizumab (AMD), making it the most direct commercialized competitor to Replenish's refillable MicroPump for the retina segment. Same patient population, same refill workflow, same ophthalmologist channel.

Emerging players

• Voyager Therapeutics (and similar ocular gene/AAV delivery peers): Emerging ocular gene therapy and AAV-delivery companies (e.g., Adverum, Regenxbio) are developing one-time treatments for AMD/DME that could compete with chronic drug delivery. They are comparable as they target the same retinal disease indications via novel delivery paradigms.
• Second Sight Medical Products: Second Sight developed the Argus II retinal prosthesis and was co-founded by Dr. Mark Humayun, Replenish's co-founder. Comparable as an early-stage, MEMS-and-ophthalmology implantable medical device company that emerged from the same BMES ERC ecosystem at USC/Caltech.
• Clearside Biomedical: Clearside Biomedical developed the SCS Microinjector for suprachoroidal drug delivery and is advancing therapies for retinal diseases including AMD and DME. Compares as a small ophthalmic drug delivery company competing for similar indications via a different delivery route.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Replenish